The company, with teams in Utah, Japan, and Massachusetts, focuses on advancing purposeful science by transforming new discoveries into meaningful treatments for cancer patients. Their robust pipeline of preclinical and advanced-stage assets targets various areas such as oncogenic pathways and survival mechanisms to address unmet clinical needs in oncology. SDP Oncology encompasses discovery research, external innovation, clinical development, and commercialization, aiming to bring breakthrough innovation to positively impact cancer patients today and in the future.